GEN Exclusives

More »

GEN News Highlights

More »
Dec 16, 2008

OmegaGenesis to Leverage Mayo Clinic’s Nanomaterial Research in Angiogenesis Applications

  • OmegaGenesis and Mayo Clinic have decided to work together to discover and validate nanomaterials in angiogenesis applications. The deal includes licenses for Mayo Clinic technology and patents as well as a research collaboration.

    The firm will leverage Mayo Clinic researchers’ work in which they produced a rare earth material in nano size and established nontoxicity of the material for human applications. Additionally, they have shown that the material induces endothelial cell growth and produces new blood vessels. 

    OmegaGenesis has the exclusive rights to further test angiogenesis characteristics of the nano rods developed at Mayo Clinic. The company will support ongoing research projects in early-development stages at the Clinic, and the organizations will together conduct lab tests.

    “Our goal is to supplement natural human body management and re-enable where some natural processes have stopped or diminished,” comments  Oostur Raza, president and CEO of OmegaGenesis.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »